In squamous cell carcinoma cells with mutated FAK, HDAC and FAK inhibitors work synergistically to arrest cellular proliferation and tumor growth, emphasizing the importance of collaborations of multiple targets [151]. This evidence concerns the gene PTK2 and neoplasm.